ARUP LABORATORIES | aruplab.com
500 Chipeta Way, Salt Lake City, Utah 84108-1221
phone: 801-583-2787, toll free: 800-522-2787
Jonathan R. Genzen, MD, PhD, Chief Medical Officer

PATIENT REPORT

Patient Age/Sex: Male

Specimen Collected: 15-Jun-23 09:30

NR4A3 Rearrangement by FISH |**Received: 15-Jun-23 09:31** **Report/Verified: 15-Jun-23 09:32**

Procedure	Result	Units	Reference Interval
NR4A3 FISH Result	Negative [f1]		
Total Cell Count	50		
Scoring Method	Manual		
NR4A3 FISH Reference Number	ABC123		
NR4A3 FISH Source	Tissue [i1]		

Result Footnote

f1: NR4A3 FISH Result

This result has been reviewed and approved by Controls performed as expected.

Test Information

i1: NR4A3 FISH Source

INTERPRETIVE INFORMATION: NR4A3(9q22.33-q31.1), FISH

Fluorescence in situ hybridization (FISH) analysis was performed on a section from a paraffin embedded tissue block using differentially labeled fluorescent probes targeting the upstream (5') and downstream (3') flanking regions of the NR4A3 gene (Agilent Technologies). Cells were evaluated from regions of tumor identified on histopathologic review of a matching hematoxylin and eosin stained section. Controls performed appropriately.

This test is designed to detect rearrangements involving the NR4A3 gene, but it does not identify a specific partner gene. An abnormal signal pattern seen in 25 percent or more of the tumor cells evaluated is considered a positive result. Based on the assay performance during test validation, the test is expected to detect 100 percent of NR4A3 rearrangements in patients with NR4A3 rearranged tumors, except for rare instances of cryptic rearrangements. Assay range and limit of detection were generated using normal and known positive cases respectively.

Identification of a rearrangement of the NR4A3 gene locus is useful for diagnosis of Extraskeletal Myxoid Chondrosarcoma (EMCS)and salivary acinic cell carcinoma. NR4A3 rearrangements may also rarely be found in certain other tumors. Correlation with histopathologic and clinical findings is, therefore, essential for complete interpretation of this study.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.